Molecular residual disease (MRD) testing is moving into the next phase of precision oncology, extending molecular insight past diagnosis and treatment selection into post-treatment monitoring, surveillance and survivorship.
For health systems, the question is not whether to add another test. It is whether the governance, workflows and follow-up pathways exist to use the information responsibly and consistently — and most of those decisions have to be settled before the first order goes in.
This session will walk through the operating model MRD requires, using colorectal cancer as a practical implementation anchor and breast cancer as a model for pathway discipline. The focus is on what it takes to translate molecular insight into coordinated cancer care.
Learnings include:
- Why MRD is a health system operating-model question not only a clinical testing innovation
- The workflow decisions to make before scaling, including eligibility, timing, ordering ownership, result routing and escalation
- How colorectal cancer can serve as a practical starting point for MRD pathway design
- How breast cancer pathway discipline, including timely use of genomic testing, informs MRD readiness across oncology
This webinar is sponsored by Exact Sciences, now Abbott.